Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Jan 19, 2024

SELL
$2.12 - $4.18 $51,092 - $100,738
-24,100 Reduced 18.84%
103,800 $420,000
Q3 2023

Oct 19, 2023

BUY
$2.66 - $10.04 $296,324 - $1.12 Million
111,400 Added 675.15%
127,900 $344,000
Q2 2023

Jul 18, 2023

BUY
$7.28 - $11.82 $120,120 - $195,030
16,500 New
16,500 $153,000

Others Institutions Holding THRX

About Theseus Pharmaceuticals, Inc.


  • Ticker THRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,713,400
  • Description
  • Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also ...
More about THRX
Track This Portfolio

Track Denali Advisors LLC Portfolio

Follow Denali Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Denali Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Denali Advisors LLC with notifications on news.